BE Pilot Project and Guidelines
The basic concept of Biomonitoring Equivalents (BEs) – concentrations of chemicals or their metabolites in blood or urine consistent with existing exposure guidance values – was introduced as a method for integrating pharmacokinetic data with existing chemical risk assessments to provide a screening tool to interpret human biomonitoring data in a public health risk context. While the original conception of the BE and general approaches for calculating BEs were outlined in Hays et al. (2007), guidance on specific approaches and implementation for derivation and communication of BEs remained to be developed. The Biomonitoring Equivalents Pilot Project was launched to implement the concept for case study chemicals and to develop an initial set of guidelines for the derivation and communication of BE values.
The Pilot Project consisted of two main components: development of case studies for several example chemicals, and consultation in an expert workshop with a panel of experts on the technical and communications issues identified in the process of BE development for the case study chemicals. The Biomonitoring Equivalents Pilot Project was designed from the outset to engage interested parties in a collaborative effort.
The expert workshop resulted in the publication of guidelines for the derivation and communication of Biomonitoring Equivalents in the journal Regulatory Toxicology and Pharmacology.